Treatment Status and Economic Burden of People with Hemophilia in Mainland China: A Systematic Review

Yan-Ji QU,Huan YIN,Yuan-jie PANG,Xiao-lu NIE,Peng DONG,Si-yan ZHAN

DOI: https://doi.org/10.7507/1672-2531.20130032

2013-01-01

Abstract:Objective To be aware of the treatment status and economic burden of people with hemophilia(PWH) in mainland China,so as to seek the optimal therapy for them.Methods e relevant Chinese and English databases such as CBM,CNKI,VIP,WanFang Database,PubMed,EMbase and e Cochrane Library(Issue 6 of 12,June 2011) were searched in June,2011.e economic analyses and studies on PWH treatment and economic burden published from 1980 to 2011 were collected.Results e diagnosis and treatment of PWH in mainland China lagged behind.More than 30% of PWH did not receive or occasionally received treatment,and less than 10% received prophylactic therapy.Lots of PWHs still used FFP or cryoglobulin which were easily to cause blood-borne viral diseases.More than half of PWH families could a ord a little or completely could not a ord the therapy.Low dose prophylactic therapy was cost-e cient than on-demand therapy.Based on the therapy status,it was estimated that approximately RMB 53 844 yuan per year per patient should be put into practice in order to have PWH received low-dose prophylactic therapy,and to prevent 80% of bleeding.Conclusion PWH in mainland China is poor in treatment status and heavy in economic burden,so it is an optimal way to adopt comprehensive care model and low-dose prophylactic therapy in mainland China.